



Rec'd PCT/PTO 10 DEC 2004



INVESTOR IN PEOPLE

Best Available Copy

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 07 JUL 2003

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

Andrew Gensey

Dated- 20 June 2003



The
Patent
Office



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

100692

2. Patent application number

(The Patent Office will fill in this part)

0213580.4

13 JUN 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB
S-151 85 Sodertalje
Sweden

Patents ADP number (if you know it)

7822448003

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

METHODS

5. Name of your agent (if you have one)

Allen F Giles

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited
Global Intellectual Property
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TG

Patents ADP number (if you know it)

6988463003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

15

Claim(s)

2

Abstract

Drawing(s)

1 + 1 *ll*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(*please specify*)

9 (Sequence Listing)

11. I/We request the grant of a patent on the basis of this application.

Signature

Lynda M Slack

Date

Authorised Signatory

12 Jun 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Lynda M Slack - 01625-516173

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

METHODS

This invention relates to polymorphisms in the human OATPF gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the OATPF gene, and to the use of OATPF polymorphism in treatment of diseases with OATPF transportable drugs.

Membrane transporters are important for the absorption of oral medications across the gastrointestinal tract, uptake in to target tissues such as the liver or brain, and excretion into the bile and urine. Changes in the activities of transporters may therefore have a significant effect on the bioavailability of clinically important drugs.

It has been reported in the literature that polymorphisms in proteins involved in drug transport can alter the function of the protein. For example, the multidrug-resistance (MDR-1) gene contains a polymorphism in exon 26 (C345T) which has been correlated with expression levels and function of MDR-1. Individuals homozygous for this polymorphisms have significantly lower duodenal MDR-1 expression and high digoxin plasma levels, suggesting this polymorphism affects the absorption and tissue concentrations of substrates of MDR-1 (S Hoffmeyer *et al.* Proceedings National Academy Science (2000) 97, 3473-3478).

The human sodium independent organic anion transporting polypeptide (OATP) F gene is a member of the OATP supergene family involved in multifunctional transport of organic anions (I. Tamai *et al.* Biochemical and Biophysical Research Communications 273, 251-260 (2000); M. Kusuvara & Y. Sugiyama Journal of Controlled Release 78 (2002) 43-54). There is an alternative nomenclature for this family as SLC21A (solute carriers) and OATPF relates to SLC21A14. A cDNA sequence encoding OATPF has been submitted to the EMBL database under accession number AF260704. A cDNA sequence encoding for OATPF has also been submitted to the EMBL database under accession number AF205076, and has been accorded the alternative name for OATPF of OATPRP5.

OATPF has a 43% identity at the amino acid level with its gene family member human OATPC (SLC21A6). OATPC has been shown to be involved in the transport of drugs involved in lipid lowering e.g. statins (D. Nakai *et al.* J Pharmacol Exp Ther 2001 297: 861-867). Statins have been referred to as a first-line therapy for patients with atherosclerotic vascular diseases (B. Hsiang *et al.* J. Biol Chem 274, 37161-37168 (1999)). Due to its sequence homology, it is likely that OATPF may transport similar substrates as OATPC. OATPF is also

homologous to a rat gene named BSAT1. BSAT1 is expressed at the blood-brain barrier in rats and human homologues of this gene may be important in transport of pharmaceutical agents into the brain.

DNA polymorphisms are variations in DNA sequence between one individual and another. DNA polymorphisms may lead to variations in amino acid sequence and consequently to altered protein structure and functional activity. Polymorphisms may also affect mRNA synthesis, maturation, transportation and stability. Polymorphisms which do not result in amino acid changes (silent polymorphisms) or which do not alter any known consensus sequences may nevertheless have a biological effect, for example by altering mRNA folding or stability.

Knowledge of polymorphisms may be used to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), Nature Biotechnology, 16, 33.

Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

The first 54bp of genomic DNA sequence immediately upstream of the OATPF protein coding sequence is set out as SEQ ID NO: 15, with the first nucleotide of the genomic DNA sequence accorded position 1. The position of the polymorphism in the genomic DNA sequence is defined with reference to SEQ ID NO: 15 unless stated otherwise or apparent from the context.

A cDNA sequence encoding OATPF is set out as SEQ ID NO: 16, with the first nucleotide of the OATPF coding region accorded position 65. All positions of polymorphisms in the human OATPF gene transcribed into messenger RNA (and thence cDNA) herein refer to the positions in SEQ ID NO: 16 unless stated otherwise or apparent
5 from the context.

All positions herein of polymorphisms in the OATPF polypeptide are defined with reference to SEQ ID NO: 17 unless stated otherwise or apparent from the context.

The present invention is based on the discovery of four polymorphisms in the human OATPF gene and one polymorphism in the genomic DNA sequence immediately upstream of
10 the human OATPF gene. The polymorphisms of the present invention may have a functional effect on the protein and hence alter the transport of pharmaceutical agents.

According to one aspect of the present invention there is provided a method for the detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at any one of the following positions: position 11-16 of SEQ ID NO:
15 15; positions 86, 505, 1339, 1991 of SEQ ID NO: 16; position 8 of SEQ ID NO: 17.

The term "human" includes both a human having or suspected of having an OATPF mediated response to a drug and an asymptomatic human who may be tested for predisposition or susceptibility to such a response. At each position the human may be homozygous for an allele or the human may be a heterozygote.

20 The term "detection of a polymorphism" refers to determination of the genetic status of an individual at a polymorphic position (in which the individual may be homozygous or heterozygous at each position).

The term "OATPF mediated response" means any disease in which changing the level of an OATPF mediated response or changing the biological activity of OATPF would be of
25 therapeutic benefit.

The term "polymorphism" includes nucleotide substitution, nucleotide insertion and nucleotide deletion, which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene and variable numbers of a repeated DNA sequence.

30 In one embodiment of the invention preferably the polymorphism is further defined as: polymorphism at position 11-16 is presence of TAAAAA and/or insertion of ACTTTGAAAG in lieu thereof;

polymorphism at position 86 is presence of A and/or G;
polymorphism at position 505 is presence of C and/or T;
polymorphism at position 1339 is presence of A and/or G;
polymorphism at position 1991 is presence of A and/or T; and

5 polymorphism at position 8 is presence of Asn and/or Asp.

The polymorphism at position 11-16 of SEQ ID NO: 15 is the result of a deletion-insertion event defined as deletion of bases 11-16 of SEQ ID NO: 15 and insertion of ACTTTGAAAG in lieu thereof. This results in an overall extra four bases and it will be appreciated by the skilled person that this will have an effect on the numbering of positions
10 downstream of this. For example, position 17 of SEQ ID NO: 15 becomes position 21 after the deletion-insertion event. It will also be appreciated by the skilled person that it may not be necessary to sequence the entire 11-16 bases or the insertion at this position to distinguish between the two alleles. For example, position 11 is either a T or an A when comparing the sequence of the two alleles.

15 In Figure 1, the polymorphism at position 11-16 is shown relative to the +1 ATG start site of the OATPF gene (position 65 as defined in SEQ ID NO: 16). Splicing of the genomic DNA sequence of Fig. 1 results in excision of the intronic region to produce a spliced 5' UTR (position 1-64 as defined in SEQ ID NO: 16) immediately upstream of the OATPF gene.

Preferred methods for detection of nucleic acid polymorphism are amplification
20 refractory mutation system and restriction fragment length polymorphism.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic
25 acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of
30 allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a

- number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMST™	Amplification refractory mutation system
b-DNA	Branched DNA
bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
DHPLC	Denaturing high performance liquid chromatography
FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OATP	Na ⁺ -independent organic anion transporting polypeptide
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis
UTR	Untranslated region

10

Table 1 - Mutation Detection Techniques

General: DNA sequencing, Sequencing by hybridisation

Scanning: PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

15 * Note: not useful for detection of promoter polymorphisms.

Hybridisation Based

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO

5 95/13399 (Public Health Inst., New York)

Extension Based: ARMS™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

Incorporation Based: Mini-sequencing, APEX

Restriction Enzyme Based: RFLP, Restriction site generating PCR

10 **Ligation Based:** OLA

Other: Invader assay

Table 2 - Signal Generation or Detection Systems

Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom

15 Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

Table 3 - Further Amplification Methods

20 SSR, NASBA, LCR, SDA, b-DNA

Table 4- Protein variation detection methods

Immunoassay

Immunohistology

Peptide sequencing

25 Immunoassay techniques are known in the art e.g. A Practical Guide to ELISA by D M Kemeny, Pergamon Press 1991; Principles and Practice of Immunoassay, 2nd edition, C P Price & D J Newman, 1997, published by Stockton Press in USA & Canada and by Macmillan Reference in the United Kingdom. Histological techniques are known in the art e.g. Theory and Practice of Histological Techniques, 4th Edition, edited by JD Bancroft and A
30 Stevens, Churchill Livingstone, 1996. Protein sequencing is described in Laboratory techniques Biochemistry and Molecular Biology, Volume 9, Sequencing of Proteins and Polypeptides, G Allen, 2nd revised edition, Elsevier, 1989.

Preferred mutation detection techniques include ARMSTTM, ALEXTM, COPS, Taqman, Molecular Beacons, RFLP, restriction site based PCR and FRET techniques, polyacrylamide gel electrophoresis and capillary electrophoresis.

Particularly preferred methods include ARMSTTM and RFLP based methods. ARMSTTM
5 is an especially preferred method.

In a further aspect, the methods of the invention are used to assess the pharmacogenetics of a drug transportable by OATPF.

Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

10 Individuals who carry particular allelic variants of the OATPF gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The methods of the invention may be useful both to
15 predict the clinical response to such agents and to determine therapeutic dose.

In a further aspect, the methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by OATPF. The present invention may be used to recognise individuals who are particularly at risk from developing such diseases.

20 In a further aspect, the methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the OATPF gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the
25 disease process whilst minimising effects on other variants.

In a further aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

According to another aspect of the present invention there is provided a human
30 OATPF gene or its complementary strand comprising a variant allelic polymorphism at one or more of positions defined herein or a fragment thereof of at least 20 bases comprising at least one novel polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 contiguous bases of the human OATPF gene and comprising an allelic
5 variant selected from any of the following:

Region	variant	Position
Exon 1	G	86 (SEQ ID NO: 16)
Exon 4	T	505 (SEQ ID NO: 16)
Exon 9	G	1339 (SEQ ID NO: 16)
Exon 14	T	1991 (SEQ ID NO: 16)
Intronic	ACTTTGAAAG	11-16 (SEQ ID NO: 15)

According to another aspect of the present invention there is provided a human OATPF gene or its complementary strand comprising a polymorphism, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least
10 20 bases comprising at least one polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

15 According to another aspect of the present invention there is provided an allele specific primer capable of detecting an OATPF gene polymorphism, preferably at one or more of the positions as defined herein.

An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between
20 alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMSTM assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3'
25 terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If
5 required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting an OATPF gene polymorphism, preferably at one or more of the positions defined herein.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more
10 preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the
15 corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

According to another aspect of the present invention there is provided an allele
20 specific primer or an allele specific oligonucleotide probe capable of detecting an OATPF gene polymorphism at one of the positions defined herein.

According to another aspect of the present invention there is provided a diagnostic kit comprising an allele specific oligonucleotide probe of the invention and/or an allele-specific primer of the invention.

25 The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

In another aspect of the invention, the polymorphisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymorphisms of
30 relatively high frequency. The OATPF gene is on chromosome 12. Low frequency polymorphisms may be particularly useful for haplotyping as described below. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal

or maternal) chromosome. If recombination within the gene is random, there may be as many as 2^n haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that polymorphisms with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency within the population, low frequency polymorphisms may be particularly useful in identifying these mutations (for examples see: De Stefano V *et al. Ann Hum Genet* (1998) 62:481-90; and Keightley AM *et al. Blood* (1999) 93:4277-83).

According to another aspect of the present invention there is provided a computer readable medium comprising at least one novel sequence of the invention stored on the medium. The computer readable medium may be used, for example, in homology searching, mapping, haplotyping, genotyping or pharmacogenetic analysis or any other bioinformatic analysis. The reader is referred to Bioinformatics, A practical guide to the analysis of genes and proteins, Edited by A D Baxevanis & B F F Ouellette, John Wiley & Sons, 1998. Any computer readable medium may be used, for example, compact disk, tape, floppy disk, hard drive or computer chips.

The polynucleotide sequences of the invention, or parts thereof, particularly those relating to and identifying the polymorphisms identified herein represent a valuable information source, for example, to characterise individuals in terms of haplotype and other sub-groupings, such as investigation of susceptibility to treatment with particular drugs. These approaches are most easily facilitated by storing the sequence information in a computer readable medium and then using the information in standard bioinformatics programs or to search sequence databases using state of the art searching tools such as "GCC". Thus, the polynucleotide sequences of the invention are particularly useful as components in databases useful for sequence identity and other search analyses. As used herein, storage of the sequence information in a computer readable medium and use in sequence databases in relation to 'polynucleotide or polynucleotide sequence of the invention' covers any detectable chemical or physical characteristic of a polynucleotide of the invention that may be reduced to, converted into or stored in a tangible medium, such as a computer

disk, preferably in a computer readable form. For example, chromatographic scan data or peak data, photographic scan or peak data, mass spectrographic data, sequence gel (or other) data.

The invention provides a computer readable medium having stored thereon one or
5 more polynucleotide sequences of the invention. For example, a computer readable medium is provided comprising and having stored thereon a member selected from the group consisting of: a polynucleotide comprising the sequence of a polynucleotide of the invention, a polynucleotide consisting of a polynucleotide of the invention, a polynucleotide which comprises part of a polynucleotide of the invention, which part includes at least one of the
10 polymorphisms of the invention, a set of polynucleotide sequences wherein the set includes at least one polynucleotide sequence of the invention, a data set comprising or consisting of a polynucleotide sequence of the invention or a part thereof comprising at least one of the polymorphisms identified herein.

A computer based method is also provided for performing sequence identification,
15 said method comprising the steps of providing a polynucleotide sequence comprising a polymorphism of the invention in a computer readable medium; and comparing said polymorphism containing polynucleotide sequence to at least one other polynucleotide or polypeptide sequence to identify identity (homology), i.e. screen for the presence of a polymorphism.

20 According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug transportable by OATPF in which the method comprises:

- i) detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at one or more of: position 15-24 of SEQ ID NO: 15;
25 positions 86, 505, 1339 and 1991 of SEQ ID NO: 16; position 8 of SEQ ID NO: 17; and
- ii) administering an effective amount of the drug.

Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which statin drug or drugs to administer and/or in deciding on the effective amount of the statin drug or drugs. Statins already approved for use
30 in humans include atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin. Statins under development include rosuvastatin. The reader is referred to the following references for further information: Drugs and Therapy Perspectives (12th May 1997), 9: 1-6; Chong (1997)

Pharmacotherapy 17: 1157-1177; Kellick (1997) Formulary 32: 352; Kathawala (1991) Medicinal Research Reviews, 11: 121-146; Jahng (1995) Drugs of the Future 20: 387-404, and Current Opinion in Lipidology, (1997), 8, 362 – 368; Olsson AG, Pears J, McKellar J, Mizan J & Raza A (2001) American Journal of Cardiology 88(5): 504-508. The term “drug
5 transportable by OATPF” means that transport by OATPF in humans is an important part of a drug exerting its pharmaceutical effect in man. For example, some statins have to be transported to the liver by OATPC, which is highly homologous to OATPF, to exert their lipid lowering effects. Accordingly, OATPF is expected to be involved in statin transport.

According to another aspect of the present invention there is provided use of a drug
10 transportable by OATPF in preparation of a medicament for treating a disease in a human determined as having a polymorphism defined herein.

According to another aspect of the present invention there is provided a pharmaceutical pack comprising OATPF transportable drug and instructions for administration of the drug to humans tested for a polymorphism described therein, preferably
15 at one or more of the positions defined herein.

One of the polymorphisms of the present invention result in variation in the amino acid sequence of the translated protein. Polymorphism at position 86 as defined in SEQ ID NO: 16 results in an amino acid change from asparagine to aspartic acid at corresponding position 8 of the translated protein (Asn8Asp) as defined in SEQ ID NO: 17.

20 Thus according to another aspect of the present invention there is provided an allelic variant of human OATPF polypeptide having an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

Fragments of OATPF polypeptide are at least 10 amino acids, more preferably at least
25 15 amino acids, more preferably at least 20 amino acids. The polypeptides of the invention do not encompass naturally occurring polypeptides as they occur in nature, for example, the polypeptide is at least partially purified from at least one component with which it occurs naturally. Preferably the polypeptide is at least 30% pure, more preferably at least 60% pure, more preferably at least 90% pure, more preferably at least 95% pure, and more preferably at
30 least 99% pure.

According to another aspect of the present invention there is provided an antibody specific for an allelic variant of human OATPF polypeptide having an aspartic acid at position

8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

Antibodies can be prepared using any suitable method. For example, purified polypeptide may be utilized to prepare specific antibodies. The term "antibodies" is meant to include polyclonal antibodies, monoclonal antibodies, and the various types of antibody constructs such as for example $F(ab')_2$, Fab and single chain Fv. Antibodies are defined to be specifically binding if they bind the allelic variant of OATPF with a K_a of greater than or equal to about $10^7 M^{-1}$. Affinity of binding can be determined using conventional techniques, for example those described by Scatchard et al., *Ann. N.Y. Acad. Sci.*, 51:660 (1949).

Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice or rats, using procedures that are well-known in the art. In general, antigen is administered to the host animal typically through parenteral injection. The immunogenicity of antigen may be enhanced through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant. Following booster

immunizations, small samples of serum are collected and tested for reactivity to antigen.

Examples of various assays useful for such determination include those described in:

Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays

(ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

Monoclonal antibodies may be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

The monoclonal antibodies of the invention can be produced using alternative techniques, such as those described by Altling-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3: 1-9 (1990) which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7: 394 (1989).

Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to ELISA" by D. M. Kemeny, Pergamon Press, Oxford, England.

According to another aspect of the invention there is provided a diagnostic kit
5 comprising an antibody of the invention.

The invention will now be illustrated but not limited by reference to the following Examples and Figure 1 is a schematic representation of the genomic DNA sequence upstream of Exon 1 of the OATPF gene, and shown relative to the corresponding nucleotide positions of SEQ ID NO: 15 and SEQ ID NO: 16. All temperatures are in degrees Celsius.

10 In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

AMPLITAQ™, available from Perkin-Elmer Cetus, may be used as the source of thermostable DNA polymerase.

General molecular biology procedures can be followed from any of the methods
15 described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989) or in "Current Protocols in Molecular Biology Volumes 1-3", edited by F M Asubel, R Brent and R E Kingston; published by John Wiley, 1998.

EXAMPLES

20 Example 1

Identification of Polymorphisms

1. Methods

The cDNA sequence of OATPF (AF260704) was used to identify the genomic position of the gene and obtain genomic DNA sequence. The genomic DNA sequence was
25 used to design PCR primers to amplify over the exons and intron/exon boundaries of the full length of the OATP gene. Twenty-nine individual Caucasian genomic DNA samples were used as templates for PCR amplification. The products were then sequenced by dye-primer sequencing using Amersham's MegaBACE™ technology. The alignment of sequence traces enabled the identification of polymorphisms. The frequency of the polymorphisms was
30 confirmed using genomic DNA from 20 individuals by primer extension analysis by DHPLC using the WAVE® system by Transgenomics and also by sequencing as described above. The deletion-insertion event was confirmed by sequencing in the forward and reverse direction.

PCR products

Polymorphism	PCR forward oligo	PCR reverse oligo	Primer used for confirmation of polymorphism
Exon 1	(SEQ ID NO: 1)	(SEQ ID NO: 2)	(SEQ ID NO: 3)
Exon 4	(SEQ ID NO: 4)	(SEQ ID NO: 5)	(SEQ ID NO: 6)
Exon 9	(SEQ ID NO: 7)	(SEQ ID NO: 8)	(SEQ ID NO: 9)
Exon 14	(SEQ ID NO: 10)	(SEQ ID NO: 11)	(SEQ ID NO: 12)
Intronic	(SEQ ID NO: 13)	(SEQ ID NO: 14)	N/a

PCR conditions:

- 5 18µl ABgene 2mM Reddy load including Taq polymerase
- 1µl 5µM primer pair mix
- 1µl genomic DNA (various individuals)

PCR programme:

- 10 94°C 1min; (94°C 30sec, 58°C 30sec, 72°C 2 min) for 34 cycles; 72°C 10 min.

2. OATPF Polymorphisms

- 15 Sequencing of DNA from 20 individuals identified the following 5 polymorphisms in the OATPF DNA sequence:

Position of SEQ ID NO 16	Region	Variation	Resultant codon change	Protein sequence SEQ ID NO 17	Frequency variant allele
86	Exon 1	A/G	aat-gat	Asn8Asp	0.03G
505	Exon 4	C/T	N/a	Ser147Ser	0.46T
1339	Exon 9	A/G	N/a	Ala425Ala	0.05G
1991	Exon 14	C/T	N/a	Leu643Leu	0.25T

Position of SEQ ID NO: 15	Region	Variation	Resultant codon change	Protein sequence SEQ ID NO 17	Frequency variant allele
11-16	Intronic	TAAAAA/ACTTTGA AAG	N/a	N/a	0.06ACTTTGAAAG

Claims

1. A method for the detection of a polymorphism in OATPF in a human which method comprises determining the sequence of the human at any one of the following positions:
 - 5 position 11-16 of SEQ ID NO: 15;
 - positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
 - position 8 of SEQ ID NO: 17.
2. A method according to claim 1 wherein the polymorphism is further defined as:
 - 10 polymorphism at position 11-16 is presence of TAAAAA and/or insertion of ACTTTGAAAG
 - polymorphism at position 86 is presence of A and/or G;
 - polymorphism at position 505 is presence of C and/or T;
 - polymorphism at position 1339 is presence of A and/or G;
 - polymorphism at position 1991 is presence of A and/or T; and
 - 15 polymorphism at position 8 is presence of Asn and/or Asp.
3. A method according to claim 1 or 2 wherein the method for detection of a nucleic acid polymorphism is selected from amplification refractory mutation system and restriction fragment length polymorphism.
4. Use of a method defined in any of claims 1-3 to assess the pharmacogenetics of a drug
 - 20 transportable by OATPF.
5. A polynucleotide comprising at least 20 contiguous bases of the human OATPF gene and comprising an allelic variant selected from any of the following:

Region	variant	Position
Exon 1	G	86 (SEQ ID NO: 16)
Exon 4	T	505 (SEQ ID NO: 16)
Exon 9	G	1339 (SEQ ID NO: 16)
Exon 14	T	1991 (SEQ ID NO: 16)
Intronic	ACTTTGAAAG	11-20 (SEQ ID NO: 15)
6. An allele specific primer capable of detecting an OATPF gene polymorphism at
 - 25 position 11-16 of SEQ ID NO: 15, and position 86, 505, 1339 and 1991 of SEQ ID NO: 16.
7. An allele specific oligonucleotide probe capable of detecting a OATPF gene polymorphism at position 11-16 of SEQ ID NO: 15 and position 86, 505, 1339 and 1991 of SEQ ID NO: 16.

8. A diagnostic kit comprising an allele specific oligonucleotide probe of claim 7 and/or an allele-specific primer of claim 6.
9. A method of treating a human in need of treatment with a drug transportable by OATPF in which the method comprises:
 - 5 i) detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at one or more of:
position 11-16 of SEQ ID NO: 15;
positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
position 8 of SEQ ID NO: 17; and
 - 10 ii) administering an effective amount of the drug.
10. Use of a drug transportable by OATPF in preparation of a medicament for treating a disease in a human determined as having a polymorphism at one of the following positions:
position 11-16 of SEQ ID NO: 15;
positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
- 15 position 8 of SEQ ID NO: 17.
11. An allelic variant of human OATPF polypeptide comprising an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.
12. An antibody specific for an allelic variant of human OATPF polypeptide as described
20 herein having an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.
13. A diagnostic kit comprising an antibody of claim 12.

- 1 -
SEQUENCE LISTING

<110> ASTRAZENECA AB

5 <120> METHODS

<130> JHU/100692-1 GB 09APR02

<140>

10 <141>

<160> 17

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 40

<212> DNA

<213> Artificial Sequence

20

<400> 1

actgtaaaac gacggccagt aatgaggctt aaactgggca

40

25 <210> 2

<211> 40

<212> DNA

<213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence:PCR reverse
primer OATPF-1R

<400> 2

35 accaggaaac agctatgacc gtagagatt gcttgcaccg

40

<210> 3

<211> 20

40 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Validation
primer

45

<400> 3
tggacacttc atccaaagaa

20

5

<210> 4
<211> 41
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Description of Artificial Sequence:PCR forward
primer OATPF-2F

15

<400> 4
actgtaaaac gacggccagt ctatgagcca gatcttctgg c

41

20

<210> 5
<211> 43
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Description of Artificial Sequence:PCR reverse
primer OATPF-2R

30

<400> 5
accaggaaac agctatgacc cagaagcttt gaaagatttt ccc

43

35

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

40

<220>
<223> Description of Artificial Sequence:Validation
primer

<400> 6
tattctcctt cctccaattc

20

45

<210> 7

<211> 40

<212> DNA

<213> Artificial Sequence

5 <220>

<223> Description of Artificial Sequence:PCR forward
primer OATPF-3F

<400> 7

10 actgtaaaac gacggccagt tgggcaccta attgctacct

40

<210> 8

<211> 40

15 <212> DNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence:PCR reverse
primer OATPF-3R

<400> 8

accaggaac agctatgacc tgagggaaca tacccttggt

40

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence:Validation
primer

35 <400> 9

atcagtgtgt gtggagctgc

20

<210> 10

40 <211> 40

<212> DNA

<213> Artificial Sequence

<220>

45 <223> Description of Artificial Sequence:PCR forward

primer OATPF-4F

<400> 10

actgtaaaac gacggccagt gctgttctag gcaaacaggg

40

5

<210> 11

<211> 16

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR reverse
primer OATPF-4R

15

<400> 11

ccagtagttg ggttgt

16

20 <210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence:Validation
primer

<400> 12

30 cttcttctag acatatatat

20

<210> 13

<211> 40

35 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR forward
primer OATPF-5F

40

<400> 13

actgtaaaac gacggccagt cttcagctct ttctgtgccc

40

45

<210> 14
<211> 41
<212> DNA
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence:PCR reverse
primer OATPF-5R

10 <400> 14

accaggaac agctatgacc ttccatcaaa ctaatgaggg g 41

<210> 15

15 <211> 54

<212> DNA
<213> Homo sapiens

<400> 15

20 atttttactt taaaaactaa ctttgacaga tcagagtcaa ggaatgtgtt tata 54

<210> 16

<211> 3077

25 <212> DNA

<213> Homo sapiens

<400> 16

cattgaaagg aaatggctat ctttgatctc ttcctccaga tcagagtcaa ggaatgtgtt 60
30 tataatggac acttcatcca aagaaaatat ccagttgttc tgcaaaactt cagtgaacc 120
tggtggaagg cttctcttta aaacagaata tccctcctca gaagaaaagc aaccatgctg 180
tggtgaacta aagggtgttct tgtgtgcctt gtcttttggt tactttgcca aagcattggc 240
agaaggctat ctgaagagca ccatcactca gatagagaga aggtttgata tcccttcttc 300
actggtggga gttattgatg gtagttttga aattgggaat ctcttagtta taacatttgt 360
35 tagctacttt ggagccaaac ttcacaggcc aaaaataatt ggagcagggg gtgtaatcat 420
gggagttgga aactgctca ttgcaatgcc tcagttcttc atggagcagt acaaatatga 480
gagatattct cttctctcca attccactct cagcatctct ccgtgtctcc tagagtcaag 540
cagtcaatta ccagtttcag ttatggaaaa atcaaaatcc aaaataagta acgaatgtga 600
agtggacact agctcttcca tgtggattta tgttttctct ggcaatcttc ttcgtggaat 660
40 aggagaaact ccattcagc ctttgggcat tgcctacctg gatgattttg ccagtgaaga 720
caatgcagct ttctatattg ggtgtgtgca gacgggttgca attataggac caatcttttg 780
tttctgttta ggctcattat gtgccaaact atatgttgac attggctttg taaacctaga 840
tcacataacc attaccccaa aagatcccca gtgggtagga gcctgggtggc ttggctatct 900
aatagcagga atcataagtc ttcttgacgc tgtgcctttc tggatattac caaagagttt 960
45 accaagatcc caaagtagag aggatcttaa ttcttctctc gagaaatcca agttttattat 1020

agatgatcac acagactacc aaacacccca gggagaaaat gcaaaaataa tggaaatggc 1080
 aagagatttt cttccatcac tgaagaatct ttttggaac ccagtatact tcctatat 1140
 atgtacaagc actgttcagt tcaattctct gtccggcatg gtgacgtaca aaccaaagta 1200
 cattgagcag cagtatggac agtcacccct cagggccaac tttgtgatcg ggctcatcaa 1260
 5 cattccagca gtggcccttg gaatattctc tggggggata gttatgaaaa aattcagaat 1320
 cagtgtgtgt ggagctgcaa aactctactt gggatcatct gtctttgggtt acctcctatt 1380
 tctttccctg tttgactggt gctgtgaaaa ttctgatgtg gcaggactaa ctgtctccta 1440
 ccaaggaacc aaacctgtct cttatcatga acgagctctc ttttcagatt gcaactcaag 1500
 atgcaaatgt tcagagacaa aatgggaacc catgtgoggt gaaaatggaa tcacatatgt 1560
 10 atcagcttgt cttgctggtt gtcaaacctc caacaggagt ggaaaaata ttatatatta 1620
 caactgcact tgtgtgggaa ttgcagcttc taaatccgga aattcctcag gcatagtggg 1680
 aagatgtcag aaagacaatg gatgtcccca aatgtttctg tatttccttg taatttcagt 1740
 catcacatcc tatactttat ccctagggtg catacctgga tacatattac ttctgaggtg 1800
 cattaagcca cagcttaagt cttttgcctt gggatatctac acattagcaa taagagttct 1860
 15 tgcaggaatc ccagctccag tgtatttttg agttttgatt gatacttcat gcctcaaatg 1920
 gggatttaaa agatgtggaa gtagaggatc atgcagatta tatgattcaa atgtcttcag 1980
 acatatatat ctgggactaa ctgtgatact gggcacagtg tcaattctcc taagcattgc 2040
 agtacttttc attttaaaaga aaaattatgt ttcaaaacac agaagtttta taaccaagag 2100
 agaaagaaca atgggtgtcta caagattcca aaaggaaaat taaactacaa gtgatcatct 2160
 20 gctacaaccc aactactggc caggcaagga aactcaactt tagaaacatg atgactggaa 2220
 gtcattgtct ctaattggtt gacattttgc aaacaataa attgtaatca aaagagctct 2280
 aaatttgtaa tttctttctc ttttcaaaaa atgtctactt tgttttggtc ctaggcatta 2340
 ggtaataata ctgataatat actgaaacat ataatggaag atgcagatga taaaactaat 2400
 tttgaacttt ttaatttata taaattattt tatatcactt acttatttca ctttattttg 2460
 25 ctttgtgctc attgatatat attagctgta ctcttagaag aacaattgtc tctattgtca 2520
 cacatgggta tatttaaagt aattttctgaa ctgtgtaatg tgtctagagt aagcaaatac 2580
 tgctaacaat taactcatc cttgggttcc ttcaagtatt actcctatag tattttctcc 2640
 catagctgtc ttcattctgt tattttaata atgatcttag gatggagcag aacatggaga 2700
 ggaagatttc attttaagct cctccttttc tttgaaatac aataatttat atagaaatgt 2760
 30 gtagcagcaa attatattgg ggattagaat tttgaattaa tagctctcct actattaatt 2820
 tacatgtgct ttttgtgtgg cgctataagt gactatgggt gtaaagtaat aaaattgatg 2880
 ttaacatgcc caattattgt tcttttatga attcaatgaa tttaaaacta ttgttaata 2940
 taatactgcc ccactttaat atatgtaagc aacttcctac ttatacacga cgtgttccta 3000
 aaacatgttt gaaaggtgaa tttctgaaag tctacaataa atgtaggtgt tacaacagga 3060
 35 aaaaaaaaa aaaaaaa 3077

<210> 17

<211> 712

40 <212> PRT

<213> Homo sapiens

<400> 17

Met Asp Thr Ser Ser Lys Glu Asn Ile Gln Leu Phe Cys Lys Thr Ser

45 1

5

10

15

	Val	Gln	Pro	Val	Gly	Arg	Pro	Ser	Phe	Lys	Thr	Glu	Tyr	Pro	Ser	Ser	
				20					25						30		
5	Glu	Glu	Lys	Gln	Pro	Cys	Cys	Gly	Glu	Leu	Lys	Val	Phe	Leu	Cys	Ala	
			35					40					45				
	Leu	Ser	Phe	Val	Tyr	Phe	Ala	Lys	Ala	Leu	Ala	Glu	Gly	Tyr	Leu	Lys	
		50					55					60					
10	Ser	Thr	Ile	Thr	Gln	Ile	Glu	Arg	Arg	Phe	Asp	Ile	Pro	Ser	Ser	Leu	
	65					70				75						80	
	Val	Gly	Val	Ile	Asp	Gly	Ser	Phe	Glu	Ile	Gly	Asn	Leu	Leu	Val	Ile	
15					85					90					95		
	Thr	Phe	Val	Ser	Tyr	Phe	Gly	Ala	Lys	Leu	His	Arg	Pro	Lys	Ile	Ile	
			100						105					110			
20	Gly	Ala	Gly	Cys	Val	Ile	Met	Gly	Val	Gly	Thr	Leu	Leu	Ile	Ala	Met	
		115						120					125				
	Pro	Gln	Phe	Phe	Met	Glu	Gln	Tyr	Lys	Tyr	Glu	Arg	Tyr	Ser	Pro	Ser	
		130					135					140					
25	Ser	Asn	Ser	Thr	Leu	Ser	Ile	Ser	Pro	Cys	Leu	Leu	Glu	Ser	Ser	Ser	
	145				150						155					160	
	Gln	Leu	Pro	Val	Ser	Val	Met	Glu	Lys	Ser	Lys	Ser	Lys	Ile	Ser	Asn	
30				165						170					175		
	Glu	Cys	Glu	Val	Asp	Thr	Ser	Ser	Ser	Met	Trp	Ile	Tyr	Val	Phe	Leu	
			180						185					190			
35	Gly	Asn	Leu	Leu	Arg	Gly	Ile	Gly	Glu	Thr	Pro	Ile	Gln	Pro	Leu	Gly	
		195					200						205				
	Ile	Ala	Tyr	Leu	Asp	Asp	Phe	Ala	Ser	Glu	Asp	Asn	Ala	Ala	Phe	Tyr	
		210					215					220					
40	Ile	Gly	Cys	Val	Gln	Thr	Val	Ala	Ile	Ile	Gly	Pro	Ile	Phe	Gly	Phe	
	225					230					235					240	
	Leu	Leu	Gly	Ser	Leu	Cys	Ala	Lys	Leu	Tyr	Val	Asp	Ile	Gly	Phe	Val	
45					245					250					255		

	Asn	Leu	Asp	His	Ile	Thr	Ile	Thr	Pro	Lys	Asp	Pro	Gln	Trp	Val	Gly	
				260					265					270			
5	Ala	Trp	Trp	Leu	Gly	Tyr	Leu	Ile	Ala	Gly	Ile	Ile	Ser	Leu	Leu	Ala	
				275				280					285				
	Ala	Val	Pro	Phe	Trp	Tyr	Leu	Pro	Lys	Ser	Leu	Pro	Arg	Ser	Gln	Ser	
		290					295					300					
10	Arg	Glu	Asp	Ser	Asn	Ser	Ser	Ser	Glu	Lys	Ser	Lys	Phe	Ile	Ile	Asp	
	305				310						315					320	
	Asp	His	Thr	Asp	Tyr	Gln	Thr	Pro	Gln	Gly	Glu	Asn	Ala	Lys	Ile	Met	
15				325						330					335		
	Glu	Met	Ala	Arg	Asp	Phe	Leu	Pro	Ser	Leu	Lys	Asn	Leu	Phe	Gly	Asn	
			340						345					350			
20	Pro	Val	Tyr	Phe	Leu	Tyr	Leu	Cys	Thr	Ser	Thr	Val	Gln	Phe	Asn	Ser	
			355					360					365				
	Leu	Phe	Gly	Met	Val	Thr	Tyr	Lys	Pro	Lys	Tyr	Ile	Glu	Gln	Gln	Tyr	
	370					375						380					
25	Gly	Gln	Ser	Ser	Ser	Arg	Ala	Asn	Phe	Val	Ile	Gly	Leu	Ile	Asn	Ile	
	385					390					395					400	
	Pro	Ala	Val	Ala	Leu	Gly	Ile	Phe	Ser	Gly	Gly	Ile	Val	Met	Lys	Lys	
30				405						410					415		
	Phe	Arg	Ile	Ser	Val	Cys	Gly	Ala	Ala	Lys	Leu	Tyr	Leu	Gly	Ser	Ser	
				420					425					430			
35	Val	Phe	Gly	Tyr	Leu	Leu	Phe	Leu	Ser	Leu	Phe	Ala	Leu	Gly	Cys	Glu	
		435						440					445				
	Asn	Ser	Asp	Val	Ala	Gly	Leu	Thr	Val	Ser	Tyr	Gln	Gly	Thr	Lys	Pro	
	450						455					460					
40	Val	Ser	Tyr	His	Glu	Arg	Ala	Leu	Phe	Ser	Asp	Cys	Asn	Ser	Arg	Cys	
	465					470					475					480	
	Lys	Cys	Ser	Glu	Thr	Lys	Trp	Glu	Pro	Met	Cys	Gly	Glu	Asn	Gly	Ile	
45						485				490					495		

Thr Tyr Val Ser Ala Cys Leu Ala Gly Cys Gln Thr Ser Asn Arg Ser
 500 505 510

5 Gly Lys Asn Ile Ile Phe Tyr Asn Cys Thr Cys Val Gly Ile Ala Ala
 515 520 525

Ser Lys Ser Gly Asn Ser Ser Gly Ile Val Gly Arg Cys Gln Lys Asp
 530 535 540

10

Asn Gly Cys Pro Gln Met Phe Leu Tyr Phe Leu Val Ile Ser Val Ile
 545 550 555 560

Thr Ser Tyr Thr Leu Ser Leu Gly Gly Ile Pro Gly Tyr Ile Leu Leu
 15 565 570 575

Leu Arg Cys Ile Lys Pro Gln Leu Lys Ser Phe Ala Leu Gly Ile Tyr
 580 585 590

20 Thr Leu Ala Ile Arg Val Leu Ala Gly Ile Pro Ala Pro Val Tyr Phe
 595 600 605

Gly Val Leu Ile Asp Thr Ser Cys Leu Lys Trp Gly Phe Lys Arg Cys
 610 615 620

25

Gly Ser Arg Gly Ser Cys Arg Leu Tyr Asp Ser Asn Val Phe Arg His
 625 630 635 640

Ile Tyr Leu Gly Leu Thr Val Ile Leu Gly Thr Val Ser Ile Leu Leu
 30 645 650 655

Ser Ile Ala Val Leu Phe Ile Leu Lys Lys Asn Tyr Val Ser Lys His
 660 665 670


35 Arg Ser Phe Ile Thr Lys Arg Glu Arg Thr Met Val Ser Thr Arg Phe
 675 680 685

Gln Lys Glu Asn Tyr Thr Thr Ser Asp His Leu Leu Gln Pro Asn Tyr
 690 695 700

40

Trp Pro Gly Lys Glu Thr Gln Leu
 705 710

Figure 1



This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**